Compare ON Holding AG (ONON) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Travere Therapeutics Inc. Common Stock — how do they compare? ON Holding AG trades at $35.28 (market cap $11.86B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: ON Holding AG is far larger — about 2.4× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ONON | TVTX | |
|---|---|---|
Market Cap | $11.86B | $4.88B |
Volume | 8,624,555 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $67.52 |
52-Week Low | $26.76 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $11.02B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $35.49, up 0.4% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.44, and announced a $1 billion share buyback program through 2029 alongside ambitious long-term growth targets. Revenue for 2025 was $3.01 billion with a net income margin of 12.3% and robust cash flow from operations of $359.5 million.
The outlook is positive, driven by earnings momentum, strategic expansion, and shareholder returns, but risks include high valuation multiples and competitive pressures. Analyst consensus is strongly bullish with a $42.26 price target, suggesting potential upside from current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
